Comparing GSK (NYSE:GSK) & Eyepoint Pharmaceuticals (NASDAQ:EYPT)

GSK (NYSE:GSK) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares GSK and Eyepoint Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%

Insider and Institutional Ownership

15.7% of GSK shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GSK and Eyepoint Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07 billion	2.19	$7.54 billion	$3.20	14.57
Eyepoint Pharmaceuticals	$31.37 million	8.71	-$231.96 million	($3.74)	-0.85

GSK has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GSK and Eyepoint Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2	7	1	1	2.09
Eyepoint Pharmaceuticals	1	6	4	0	2.27

GSK currently has a consensus target price of $56.50, suggesting a potential upside of 21.15%. Eyepoint Pharmaceuticals has a consensus target price of $25.70, suggesting a potential upside of 710.73%. Given Eyepoint Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than GSK.

Summary

GSK beats Eyepoint Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.